Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 5, keine Gesamtzahl für „Sprycel“
Suchtreffer
Begriffe & Kennungen
Sprycel · 4.8 · Paediatric population The safety profile of SPRYCEL administered as single-agent therapy in paediatric patient
Eintrag öffnenSprycel · 4.8 · Pulmonary arterial hypertension (PAH) PAH (pre-capillary pulmonary arterial hypertension confirmed by right he
Eintrag öffnenSprycel · 4.8 · Pulmonary arterial hypertension (PAH) PAH (pre-capillary pulmonary arterial hypertension confirmed by right he
Eintrag öffnenSprycel · 4.8 · QT Prolongation In the Phase III study in patients with newly diagnosed chronic phase CML, one patient (< 1%)
Eintrag öffnenSprycel · 4.8 · QT Prolongation In the Phase III study in patients with newly diagnosed chronic phase CML, one patient (< 1%)
Eintrag öffnenSprycel · 4.8 · Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medi
Eintrag öffnenSprycel · 4.8 · Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medi
Eintrag öffnenSprycel · 4.8 · Special population While the safety profile of SPRYCEL in elderly was similar to that in the younger populatio
Eintrag öffnenSprycel · 4.8 · Special population While the safety profile of SPRYCEL in elderly was similar to that in the younger populatio
Eintrag öffnenSprycel · 4.8 · Summary of the safety profile The data described below reflect the exposure to SPRYCEL as single-agent therapy
Eintrag öffnenSprycel · 4.8 · Summary of the safety profile The data described below reflect the exposure to SPRYCEL as single-agent therapy
Eintrag öffnenSprycel · 4.8 · Table 5: Tabulated summary of adverse reactions Infections and infestations Very common infection (including b
Eintrag öffnenSprycel · 4.8 · Table 5: Tabulated summary of adverse reactions Infections and infestations Very common infection (including b
Eintrag öffnenSprycel · 4.8 · Table 6a: Selected adverse reactions reported in a phase 3 dose optimisation study (imatinib intolerant or res
Eintrag öffnenSprycel · 4.8 · Table 6a: Selected adverse reactions reported in a phase 3 dose optimisation study (imatinib intolerant or res
Eintrag öffnenSprycel · 4.8 · Table 7: Adverse reactions reported in ≥10% of paediatric patients with Ph+ ALL treated with SPRYCEL on a cont
Eintrag öffnenSprycel · 4.8 · Table 7: Adverse reactions reported in ≥10% of paediatric patients with Ph+ ALL treated with SPRYCEL on a cont
Eintrag öffnenSprycel · 4.8 · Table 8: CTC grades 3/4 haematological laboratory abnormalities in clinical studies in patients with resistanc
Eintrag öffnenSprycel · 4.8 · Table 8: CTC grades 3/4 haematological laboratory abnormalities in clinical studies in patients with resistanc
Eintrag öffnenSprycel · 4.8 · Tabulated list of adverse reactions The following adverse reactions, excluding laboratory abnormalities, were
Eintrag öffnen